Lung Cancer Research Call-In Day – 4/13/11

(April 5, 2011)

It’s a fact – lung cancer is the leading cancer killer in America. It’s also a fact that lung cancer lags far behind other cancers when it comes to research funding. Want to help change this and get the #1 cancer killer the research dollars it deserves?  Join us for the Lung Cancer Research Call-In Day on Wednesday, April 13th!

Recent cuts to the budget of the National Institutes of Health (NIH), passed by the U.S. House of Representatives, could have a dire effect on NIH’s ability to continue its essential research efforts – including those that target lung cancer. The American Lung Association is calling on everyone to help fight for additional federal funding for lung cancer research. Join our Lung Cancer Research Call-In Day to speak as one voice with others across the nation.

Who to call:
Call you Senators and Representative in Congress. Find your representatives and their phone numbers by clicking here.

When to call:
Wednesday, April 13th, 2011. Our voice will have more impact if we all make ourselves heard on the same day! 

What to say:
Not sure what to say? We’ve prepared an easy-to-follow set of talking points to help you get the message across that we can’t afford to cut funding for lung cancer research.

Where to learn more:
Go to for all you need to make your voice heard!

About lung cancer:

  • Lung cancer is the leading cancer killer in the U.S, killing almost 160,000 people every year.
  • Lung cancer has one of the highest incidence rates and one of the lowest survival rates.
  • Smoking is the biggest cause of this disease, but exposure to second-hand smoke, air pollution, radon, asbestos, and other occupational hazards are also factors for this dreaded disease.
  • Each year, more than 222,000 new cases are diagnosed but tragically, only 15 percent of lung cancers are diagnosed at an early stage – making most diagnoses a death sentence.
  • Lung cancer survival-rates remain at a low 16 percent. More must be done to increase lung cancer survivorship.